Pregled bibliografske jedinice broj: 737344
Pretreatment with levosimendan improves outcome in off-pump coronary artery bypass grafting
Pretreatment with levosimendan improves outcome in off-pump coronary artery bypass grafting // 23rd World Congress of the World Society of Cardio-Thoracic Surgeons : Meeting abstracts ; u: Journal of Cardiothoracic Surgery 8 (2013) (S1)
Split, Hrvatska, 2013. str. 35-35 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 737344 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pretreatment with levosimendan improves outcome in off-pump coronary artery bypass grafting
Autori
Husedžinović, Ino ; Bradić, Nikola
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
23rd World Congress of the World Society of Cardio-Thoracic Surgeons : Meeting abstracts ; u: Journal of Cardiothoracic Surgery 8 (2013) (S1)
/ - , 2013, 35-35
Skup
World Congress of the World Society of Cardio-Thoracic Surgeons (23 ; 2013)
Mjesto i datum
Split, Hrvatska, 12.09.2013. - 15.09.2013
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
levosimendan; OPCABG; coronary artery bypass grafting
Sažetak
Levosimendan, calcium sensitizer, induces contractility by binding to troponin C without increasing intracellular calcium concentration. We tested the hypothesis that levosimendan could produce early and prolonged beneficial effect on left ventricular (LV) systolic function in patients with normal LV function undergoing off-pump coronary artery bypass grafting (OPCABG). Loading dose of levosimendan at low-dose (12 mcg/kg), highdose (24 mcg/kg) or placebo were administered in thirty-one patients in randomized controlled study. Bolus thermodilution by pulmonary artery catheter used for cardiac output (CO) measuring. Numerical data were described by median. To compare the three independent groups (low or high-dose levosimendan or placebo) the Kruskal-Walis test was applied. For comparing time points in one group, we tested the differences in time within each group with the Friedman test. Significant increase in CO occurred after low-dose (p = 0.001) and high-dose levosimendan (p < 0.001). CO was higher in all measurements in patients receiving low-dose levosimendan versus patients received placebo, but didn’t rich significance. In patients receiving low-dose levosimendan, compared with baseline measurement, CO was higher 20 minutes after infusion (p = 0.080) and 48 h after surgery (p=0.067). Similar alteration in CO measurements occurred after high-dose comparing with low-dose levosimendan. Furthermore, CO was significantly higher in patients receiving high-dose levosimendan compared with those receiving placebo, 20 min after infusion (p = 0.021) and 48 h after surgery (p = 0.006). Compared with baseline measurement, all values of CO were significantly higher in patients treated with high-dose levosimendan (p = 0.005 for all). Levosimendan produces early and prolonged beneficial effect on left ventricular performance in patients with preoperative normal LV function undergoing OPCABG surgery, and this effect is dose dependent.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Dubrava"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE